Advertisement

Decreased concentration of protease inhibitors: possible contributors to allodynia and hyperalgesia in women with vestibulodynia

      Objective

      Women with vestibulodynia exhibit increased pain sensitivity to contact with the vaginal vestibule as well as with vaginal penetration. The mechanism(s) responsible for this effect remains incompletely defined. Based on reports of a possible role for proteases in induction of pain, we compared levels of proteases and protease inhibitors in vaginal secretions from women with vestibulodynia and controls.

      Study Design

      Vaginal secretions from 76 women with vestibulodynia and from 41 control women were assayed by an enzyme-linked immunosorbent assay for the protease inhibitors, secretory leukocyte protease inhibitor (SLPI) and human epididymis protein-4 (HE-4), and the proteases, kallikrein-5 and cathepsins B and S. Concentrations between subjects and controls were compared and levels related to clinical and demographic variables.

      Results

      Concentrations of HE-4 and SLPI were markedly reduced in vaginal samples from women with vestibulodynia compared with controls (P ≤ .006). All other compounds were similar in both groups. HE-4 (P = .0195) and SLPI (P = .0033) were lower in women with secondary, but not primary, vestibulodynia than in controls. Subjects who had constant vulvar pain had lower levels of HE-4 and SLPI than did healthy control women (P ≤ .006) or women who experienced vulvar pain only during sexual intercourse (P ≤ .0191). There were no associations between HE-4 or SLPI levels and event associated with symptom onset, duration of symptoms, age, number of lifetime sexual partners, or age at sex initiation.

      Conclusion

      Insufficient vaginal protease inhibitor production may contribute to increased pain sensitivity in an undefined subset of women with secondary vestibulodynia who experience constant vulvar pain.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Witkin S.S.
        • Gerber S.
        • Ledger W.J.
        Differential characterization of women with vulvar vestibulitis syndrome.
        Am J Obstet Gynecol. 2002; 187: 589-594
        • Foster D.C.
        • Hasday J.D.
        Elevated tissue levels of interleukin-1β and tumor necrosis factor-α in vulvar vestibulitis.
        Obstet Gynecol. 1997; 89: 291-296
        • Foster D.C.
        • Piekarz K.H.
        • Murant T.I.
        • LaPoint R.
        • Haidaris C.G.
        • Phipps R.P.
        Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis.
        Am J Obstet Gynecol. 2007; 196: 346.e1-346.e8
        • Chaim W.
        • Meriwether C.
        • Gonik B.
        • Qureshi F.
        • Sobel J.D.
        Vulvar vestibulitis subjects undergoing surgical intervention: a descriptive analysis and histopathological correlates.
        Eur J Obstet Gynecol Reprod Biol. 1996; 68: 165-168
        • Bornstein J.
        • Goldschmid N.
        • Sabo E.
        Hyperinnervation and mast cell activation may be used as histopathologic diagnostic criteria for vulvar vestibulitis.
        Gynecol Obstet Invest. 2004; 58: 171-178
        • Westrom L.V.
        • Willen R.
        Vestibular nerve cell proliferation in vulvar vestibulitis syndrome.
        Obstet Gynecol. 1998; 91: 572-576
        • Vergnolle N.
        • Bunnett N.W.
        • Sharkey K.A.
        • et al.
        Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway.
        Nat Med. 2001; 7: 821-826
        • Lam D.K.
        • Schmidt B.L.
        Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway.
        Pain. 2010; 149: 263-272
        • King A.E.
        • Critchley H.O.D.
        • Kelly R.W.
        Presence of secretory leukocyte protease inhibitor in human endometrium and first trimester decidua suggests an antibacterial protective role.
        Mol Hum Reprod. 2000; 6: 191-196
        • Orfanelli T.
        • Jayaram A.
        • Doulaveris G.
        • Forney L.J.
        • Ledger W.J.
        • Witkin S.S.
        Human epididymis protein 4 and secretory leukocyte protease inhibitor in vaginal fluid: relation to vaginal components and bacterial composition.
        Reprod Sci. 2014; 21: 538-542
        • Shaw J.L.
        • Smith C.R.
        • Diamandis E.P.
        Proteomic analysis of human cervico-vaginal fluid.
        J Proteome Res. 2007; 6: 2859-2865
        • Shaw J.L.
        • Diamandis E.P.
        A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology.
        Biol Chem. 2008; 389: 681-688
        • Vergnolle N.
        • Wallace J.L.
        • Bunnett N.W.
        • Hollenberg M.D.
        Protease-activated receptors in inflammation, neuronal signaling and pain.
        Trends Pharmacol Sci. 2001; 22: 146-152
        • Jeremias J.
        • Ledger W.J.
        • Witkin S.S.
        Interleukin 1 receptor antagonist gene polymorphism in women with vulvar vestibulitis.
        Am J Obstet Gynecol. 2000; 182: 283-285
        • Babula O.
        • Danielsson I.
        • Sjoberg I.
        • Ledger W.J.
        • Witkin S.S.
        Altered distribution of mannose-binding lectin alleles at exon 1 codon 54 in women with vulvar vestibulitis syndrome.
        Am J Obstet Gynecol. 2004; 191: 762-766
        • Foster D.C.
        • Sazenski T.M.
        • Stodgell C.J.
        Impact of genetic variation in interleukin-1 receptor antagonist and melanocortin-1 receptor genes on vulvar vestibulitis syndrome.
        J Reprod Med. 2004; 49: 503-509
        • Lev-Sagie A.
        • Linhares I.M.
        • Ledger W.J.
        • Witkin S.S.
        A manganese superoxide dismutase gene polymorphism and development of vulvar vestibulitis syndrome.
        It J Gynaecol Obstet. 2010; 22: 59-64
        • Zolnoun D.A.
        • Rohl J.
        • Moore C.G.
        • Perinetti-Liebert C.
        • Lamvu G.M.
        • Maixner W.
        Overlap between orofacial pain and vulvar vestibulitis syndrome.
        Clin J Pain. 2008; 24: 187-191
        • Bornstein J.
        • Maman M.
        • Abramovici H.
        “Primary” versus “secondary” vulvar vestibulitis: one disease, two variants.
        Am J Obstet Gyencol. 2001; 184: 28-31
        • Granot M.
        • Frieddman M.
        • Yarnitsky D.
        • Tamir A.
        • Zimmer E.Z.
        Primary and secondary vulvar vestibulitis syndrome: systematic pain perception and psychophysical characteristics.
        Am J Obstet Gynecol. 2004; 191: 138-142

      Linked Article

      • February 2015 (vol. 212, no. 2, page 184)
        American Journal of Obstetrics & GynecologyVol. 222Issue 6
        • Preview
          Jayaram A, Esbrand F, Dulaveris G, et al. Decreased concentration of protease inhibitors: possible contributors to allodynia and hyperalgesia in women with vestibulodynia. Am J Obstet Gynecol 2015;212:184.e1-4.
        • Full-Text
        • PDF